K. Cerci and P. Patir, “Ruxolitinib as a therapy choice for refractory pruritus in a patient with essential thrombocythemia with CALR mutation”, Glob J Medical Clin Case Rep, vol. 10, no. 1, pp. 001–002, Jan. 2023.